RAFAEL HOLDINGS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
RAFAEL HOLDINGS, INC. (RFL) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $32.00 thousand as of 2026-04-30, per its 10-Q filed 2026-06-11.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-06-11
- 2026-04-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $32.00K.
- 2026-01-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $65.00K.
- 2025-10-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $98.00K.
- 2025-04-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $33.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-04-30 | $32.00K 10-Q · filed 2026-06-11 |
| 2026-01-31 | $65.00K 10-Q · filed 2026-03-16 |
| 2025-10-31 | $98.00K 10-Q · filed 2025-12-12 |
| 2025-04-30 | $33.00K 10-Q · filed 2025-06-11 |
| 2025-01-31 | $72.00K 10-Q · filed 2025-03-14 |
| 2024-04-30 | $49.00K 10-Q · filed 2024-06-14 |
| 2024-01-31 | $86.00K 10-Q · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |